Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Guiming Li
Observed name:
G. Li
Institution:
The University of Texas at San Antonio Health Science Center
Observed institutions:
The University of Texas at San Antonio Health Science Center,
Wuhan Union Hospital,
Jiangsu Hengrui Medicine (China),
Huazhong University of Science and Technology
ORCID:
0009-0002-3934-0507
Observed ORCID:
0009-0002-3934-0507
OpenAlex ID:
A5054113631
Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours
2019
·
H. Li
, J. Xu
, et al.
·
Annals of Oncology
·
3
PDF
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
2019
·
N. Li
, L. Wu
, et al.
·
Annals of Oncology
·
1
PDF
Figure S2 from Targeting DDR2 for Treating Pancreatic Cancer
2025
·
Chris T.P. Do
, Prabhakar Pitta Venkata
, et al.
PDF
Figure S1 from Targeting DDR2 for Treating Pancreatic Cancer
2025
·
Chris T.P. Do
, Prabhakar Pitta Venkata
, et al.
PDF
Data from Targeting DDR2 for Treating Pancreatic Cancer
2025
·
Chris T.P. Do
, Prabhakar Pitta Venkata
, et al.
Figure S4 from Targeting DDR2 for Treating Pancreatic Cancer
2025
·
Chris T.P. Do
, Prabhakar Pitta Venkata
, et al.
PDF
Supplementary Tables 1-4 from Targeting DDR2 for Treating Pancreatic Cancer
2025
·
Chris T.P. Do
, Prabhakar Pitta Venkata
, et al.
PDF
Figure S3 from Targeting DDR2 for Treating Pancreatic Cancer
2025
·
Chris T.P. Do
, Prabhakar Pitta Venkata
, et al.
PDF
Targeting DDR2 for Treating Pancreatic Cancer
2025
·
Chris T.P. Do
, Prabhakar Pitta Venkata
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
9
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type